Korean J Nephrol.
1998 Sep;17(5):762-770.
Influence of Apolipoprotein E Polymorphism into Alteration of Atherosclerotic Cardiovascular Disease in CAPD Patients
Abstract
-
Specific apolipoprotein (apo) E genotype has been suggested as a risk factor for atherosclerosis in the general population. Lipid metabolism is known to be modulated by apo E genotype. In this study, we measured apo E genotype, lipoprotein (a)[Lp (a)], apo A phenotype and other lipoproteins in 50 CAPD patients, and evaluated the association of lipid parameters with atherosclerotic cardiovascular disease. Dipyridamole thallium scan with SPECT and ankle- arm blood pressure index (AABI) were performed in all the subjects. The patients who had positive finding in at least one of the two test were considered to have atherosclerotic cardiovascular disease [CVD (+)]. Fifteen patients had evidence of cardiovascular disease. Serum Lp (a) concentration (median; interquartile range) of CVD (+) patients (n=15, 62.0 mg/dl; 29.5-82.3) was not different from that of CVD (-) patients (n=35, 65.1mg/dl; 34.3-89.9). The frequency distribution of apo (a) phenotype of CVD (+) patients did not differ from that of CVD (-) patients. In addition, there were no differences of other lipoproteins levels and lipid profiles between two group. However, significant difference in the frequency distribution of apo E genotype (E2; 6.7 vs 20%, E3; 40 vs 68.6%, E4; 53.3 vs
between CVD (+) and CVD (-) patients. After stratifying the subjects according to the apo E genotype, we observed no difference of lipid profiles, apolipoproteins and Lp (a) concentration in E2, E3, E4. Multivariate regression analysis of risk factors for CVD revealed age and the presence of apo E4 phenotype as independent risk factors of atherosclerotic cardiovascular disease. In conclusion, Apo E4 genotype could be an independent risk factor of atherosclerotic cardiovascular disease in CAPD patients.